Está en la página 1de 3

Basic Information: Size of the oncology drug market in Pakistan = 200-250 crore According to IMS, about one-third of the

$1.2-billion pharma market in Pakistan is imported. Licensed pharma companies in Pakistan = 400 (Including MNCs.) Licensed MNCs = 30 MNCs market Share: 53% Other Information Incidence of cancer in Pakistan is 730,956/annum

Cancer % Breast Cancer = 38.5% Lung Cancer = 18% of all cases Lymphomas - Hodgkin's disease or Non-Hodgkin's lymphomas = 13% Prostate cancer = 8% Leukemia = 6% Bowel cancer = 8% Bladder cancer = 5% Head, Face and Neck cancers (lip, mouth or throat) = 5% In Pakistani women the 7 most common cancers are: Breast cancer = 38.5% of all cases Cervical cancer - cancer of the neck of the womb = 6% Lymphomas - Hodgkins disease or Non-Hodgkin's lymphoma = 6% Ovarian cancer = 6% Leukemia = 5% Bowel cancer = 4% Head, Face and Neck cancers (lip, mouth or throat) = 4% Breast Cancer: Detected in young girls and onwards (52% women population in Pakistan) Breast cancer = 38.5% of all female cancers in Pakistan (death rate ratio 1/9)

Liver Cancer: Liver Cancer = 6 per 100,000 males and 4 per 100,000 females. Liver Cancer survival rate = 3-5% only. Detected in 40s & 50s (40% of the total population of Pakistan) Hoora Pharmaceutical: What should be our Vision? To make difference in humans life every second. What should be our mission statement? Safe Humanity, live healthy and longer. Pharma Direction Setting 123456789Selection of product To make feasibility report To make financial viability (setting targets and breakeven) To launch at most 3 oncology product within 6 months to 1 year Deadline April 2015 To also acquire medical devices in the disease where Hoora is going to promote its business. To set the structure of this group before launching the product? To conduct training, availability of product and distributor appointment Launching of the product Routine Marketing

Top 10 Selling Brand in US Brand Rituxan Generic Rituximab Market In US $3 billion Clinical Usage Advanced follicular lymphoma, and breast cancer Brain tumors, Breast cancer, Lung cancer, Metastatic colorectal cancer. Metastatic breast cancer Chronic myeloid leukemia and Gastrointestinal stromal tumour. Metastatic colorectal cancer Mesothelioma, Nonsmall cell lung carcinoma. Head, neck, and colorectal cancer. multiple myeloma Breast cancer, Competitor 1 DC Mab Thera 1 DC Min vs Max PKR TP 100 mg = 39,100 500 mg = 96,900 100mg=24480 400mg=97325 Company Mabion Ph I Mabion Ph III

Avastin

Bevacizumab

$2.66 billion

Herceptin Gleevec

Trastuzumab Imatinib

$1.66 billion $1.51 billion

1 DC 1 DC

440mg=110500 100mg=169575 400mg=119000

Mabion Ph I

Eloxatin Alimta

Oxaliplatin Pemetrexed

$1.2 billion $1.04 billion

9 DC 2 DC

100mg= 13600 vs 17000 100mg=16065 500mg=59500 100mg=24225

ILDONG

Erbitux Velcade Xeloda

Cetuximab Bortezomib Capicitabine

$703.3 million $692.7 million $647.6

1 DC

Mabion Ph III

1 DC

500mg=21250

ILDONG

million Tarceva Erlotinib $564.2 million

Metastatic, Metastatic colorectal cancer. Metastatic lung cancer and Metastatic pancreatic cancer.

1DC

25mg 100mg 150mg

10 promising late-stage cancer drugs 1. Carfilzomib - multiple myeloma 2. Crizotinib (PF-02341066) - lung cancer 3. GDC-0449 (vismodegib) - basal cell carcinoma 4. OncoVex - advanced melanoma 5. PLX4032 (RG7204) - melanoma 6. Ponatinib - leukemia 7. SGN-35 (brentuximab vedotin) - Hodgkin's lymphoma, anaplastic large cell lymphomas 8. Tivozanib (AV-951) - advanced renal cell carcinoma 9. T-DM1 (Trastuzumab-DM1) - breast cancer 10. XL184 (cabozantinib) - prostate cancer

También podría gustarte